Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. Each of the following terms is defined in the Section of this Agreement set forth opposite such term below: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(i) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 3.3(a) "Book-Entry Shares" Section 2.2(a) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(a) "Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals

Terms Defined Elsewhere. Each In addition to the terms defined in Section 1.1, each of the following terms is defined in the Section of this the Agreement set forth opposite such term below: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(iAccounting Rules 5.6(b) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "ADSP 8.7(g) Allocation Schedule 8.7(g) Articles of Merger 2.2 Audited Buyer Financials 7.5(a) Audited Company Financials 5.6(a) Auditor 3.3(d)(i) Bank 5.1(a) Bank Merger 2.7 Bank Merger Agreement 2.7 Bankruptcy and Equity Exception" Section Exceptions 5.2 Basket 10.6(a)(i) BOLI 2.8(a)(ii)(C) Branch Leases 5.12(a)(i) Buyer Preamble Buyer Appraisal Delivery Date 3.4(a) Buyer Covered Losses 10.6(a)(i) Buyer Disclosure Schedule Preamble to Article 7 Buyer Indemnitee 10.1 Buyer Losses 10.1 Buyer Plans 8.6(b) Cap 10.6(a)(iii) Certificate 2.6(a) Claim Notice 10.3 Closed Branches 8.17 Closing 4.1 Closing Date 4.1 Closing Payment 3.1(a) Common Interest Information 8.22(c) Company Preamble Company Appraisal Delivery Date 3.4(c) Company Disclosure Schedule Preamble to Article 5 Company Financials 5.6(a) Company Plans 5.18(a) Company Stock Recitals Damages 10.1 Derivative Transactions 5.13 Disclosure Schedule 8.11 Dispute Notice 3.3(b) Disputed Matters 3.3(b) Effective Time 2.2 Environmental Laws 5.17 Environmental Survey 8.21(a) ESOP 5.18(e) Estimated Effective Time Balance Sheet 3.2 FBCA Recitals FHLBA 5.1 Final Losses 10.4(e) Final Net Book Value 3.3(e) First Negotiation Period 3.4(b) Fiserv Contract 2.8(a)(ii)(H) Fraud 10.6(a) FRB 1.1(d) FTMC 5.1(a) FTST 5.1(a) Incumbent Counsel 8.14(a) Indemnified Party 10.3 Indemnifying Party 10.3 Interim Company Financials 5.6(a) IRS 5.18(c) Lien 5.3 Losses 10.6(b) Material Contracts 5.12(b) Material Defect 8.21(d) Material Defect Notice 8.21(c) Merger Recitals Merger Consideration 3.1(a) Monthly Financials 8.19 Negative True-Up Amount 3.3(e)(ii) Net Book Value 2.8(b) Non-Continuing Employee 8.6(a) Non-Performing 2.10(b) OCC 1.1(d) Order 5.8 Other Transferred Assets 2.9 Outside Closing Date 11.1(b)(ii) Owned Branch Property 5.16 Parent Preamble Parent Covered Losses 10.6(a)(ii) Parent Disclosure Schedule Preamble to Article 6 Parent Indemnitee 10.2 Parent Losses 10.2 Parties Preamble Permits 5.9 Permitted Real Estate Liens and Exceptions 5.16 Plaintiff Litigation 8.22(a) Policies 5.18 Pool 5.11(g) Positive True-Up Amount 3.3(e)(i) Property Examination 8.21(a) Property Review Appraisal Factors 8.21(c) Property Review Period 8.21(a) Put Date 8.16(c) Put Notice 8.16(c) Put Period 8.16(a) Qualified MAI Appraiser 3.4(a) Regulatory Approval 9.1(c) Representatives 8.3(a) Repurchase Price 8.16(g) Repurchased Loan 8.16(d) Response Period 10.4(a) Revised Effective Time Balance Sheet 3.3(a) "Book-Entry Shares" Second Negotiation Period 3.4(d) Section 2.2(a338(h)(10) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(aElection 8.7(f) "Change of Recommendation" Section 5.3(dServicing Agreement 4.2(e) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Shares 2.6 Third Appraiser 3.4(e) Third Party Action 10.4(a) Third Party Action Notice 10.4(a) Transaction Documents 5.2 Transferred Assets 2.8(a)(ii) Transferred Branch Lease 2.8(a)(ii)(D) Transferred Holding Company 401(kAssets 2.8(a)(i) Plans" Section 6.7(cTransferred Loans 2.8(a)(ii)(B) "Company Acquisition Agreement" Section 5.3(dTransferred Personal Property 2.8(a)(ii)(F) "Company Benefit Plans" Section 3.9(aTransferred Owned Branch Property 2.8(a)(ii)(E) "Company Board" Section 3.3(aTransferred Employees 8.6(b) "Company Board Recommendation" Section 3.3(aTransferred Loans 2.10(a) "Company Capitalization Date" Section 3.2(aTransferred Records 8.4 Transitional Employees 8.6(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(eTruPS 2.8(a)(i)(A) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" RecitalsTruPS Assumption 8.15 USA PATRIOT Act 5.9

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “Accounting Principles” Section "Acceptable Confidentiality 2.3(a) “Accounts Receivable” Section 3.25 “Agreement" ” Preamble “Base Stockholders’ Equity” Section 5.3(j)(i2.3(e) "Agreement" “Buyer Indemnified Parties” Section 7.2(a) “Buyer Indemnified Party” Section 7.2(a) “Buyer Indemnifying Party” Section 7.2(c) “Buyer” Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Cash Escrow Amount” Section 3.3(a2.5 “Cash Purchase Price” Section 2.1 “Closing” Section 2.4 8 “Closing Balance Sheet” Section 2.3(a) "Book-Entry Shares" “Closing Balance Sheet Delivery Date” Section 2.3(f) “Closing Debt” Section 2.2(a) "Certificate of Merger" “Closing Stockholders’ Equity” Section 1.3 "Certificates" 2.3(d) “Company Instruments” Section 3.15(g) “Company Intellectual Property” Section 3.15(a) “Company” Recitals “Continuing Employees” Section 5.6(a) “Damages” Section 7.2(a) “Escrow Account” Section 2.5 “Escrow Agreement” Section 6.2(i) “Escrow Amount” Section 2.5 “Financial Statements” Section 3.6(a) “Health Care Laws” Section 3.18(b) “Holder” Section 2.2(a) "Change of Recommendation" “Independent Accountant” Section 5.3(d2.3(a) "Closing" “Interim Financial Statements” Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k3.6(a) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company “Leased Real Property" ” Section 3.17(b3.12(b) "Company Overlap Product" “Licenses” Section 6.2(c3.8 “Material Contracts” Section 3.17(a) "Company Permits" “Net Cash Purchase Price” Section 3.7(b2.1 “Non-Competition Agreements” Section 6.2(o) "Company Preferred Stock" “Notice” Section 3.2(a7.3(a) "Company Remedial Action" “Objection Notice” Section 6.2(c7.3(d) "Company Restricted Share Awards" “Outside Date” Section 2.4(c8.1(b) "Company RSU Awards" “Permissible Carrybacks” Section 2.4(b5.9(g) "Company SEC Documents" “Post-Closing Tax Period” Section 3.4(a5.9(d) "Company Stock Option" “Pre-Closing Return” Section 2.4(a5.9(d) "Competing Proposal" “Purchase Price” Section 5.3(j)(i2.1 “Regulatory Conditions” Section 8.1(b) "Continuing Employee" “Representatives” Section 6.7(a5.4(a) "D&O Insurance Policy" “Seller Indemnified Parties” Section 6.4 "DGCL" 7.2(c) “Seller Indemnified Party” Section 1.1 "Dissenting Share" 7.2(c) “Seller Indemnifying Parties” Section 7.2(a) “Seller Indemnifying Party” Section 7.2(a) “Sellers” Preamble “Sellers’ Accountant” Section 2.3(a) "DOJ" “Shares” Recitals “Stockholders’ Equity Deficiency” Section 6.2(b2.3(b) "Effective Time" “Stockholders’ Equity Surplus” Section 1.3 "Exchange Agent" 2.3(c) “Tax Contest” Section 2.2(a5.9(d) "Exchange Fund" “Termination Date” Section 2.2(a8.1 “Third Party Claim” Section 7.4(a) "Execution Date" Preamble "FDA Laws" “Threshold” Section 3.13(a7.2(d)(i) "Federal Health Care Programs" “Transfer” Section 3.13(j5.10 “Transfer Taxes” Section 5.9(e) "FTC" “Year-End Financial Statements” Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals3.6(a)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “Agreement” Preamble “Automotives Business” Section "Acceptable Confidentiality 3.20(b) “Automotives Subsidiaries” Section 3.20(b) “Certificate of Merger” Section 1.4 “Certificates” Section 2.2(b) “Change of Recommendation” Section 5.4(e) “Closing” Section 1.4 “Closing Date” Section 1.4 “Company” Preamble “Company Acquisition Agreement" ” Section 5.3(j)(i5.4(e) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" “Company Benefit Plan” Section 3.11(a) “Company Board” Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Company Board Recommendation” Recitals “Company Bylaws” Section 3.1 “Company Certificate” Section 3.1 “Company Common Stock” Section 3.3(a) "Book-Entry Shares" “Company Disclosure Schedule” Article 3 “Company Employee” Section 2.2(a5.8(a) "Certificate of Merger" “Company Financial Advisor” Section 1.3 "Certificates" 3.23 “Company Financial Statements” Section 2.2(a3.7 “Company Material Contract” Section 3.13(a) "Change of Recommendation" “Company Options” Section 5.3(d2.4(a) "Closing" “Company Permits” Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "3.6(a) “Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Preferred Stock” Section 3.3(a) "“Company Board Recommendation" Representatives” Section 3.3(a5.3(a) "“Company Capitalization SEC Documents” Section 3.7 “Company Stock Plans” Section 2.4(a) “Company Stockholder Approval” Section 3.26 “Company Termination Fee” Section 7.2(b)(i) “Company Warrants” Section 2.5 “Confidentiality Agreement” Section 5.3(b) “Covered Persons” Section 5.9(a) “Debt Financing” Section 4.9(b) “Debt Financing Commitments” Section 4.9(b) “D&O Insurance” Section 5.9(c) “DGCL” Recitals “Dissenting Shares” Section 2.3 “Effective Time” Section 1.4 “Environmental Claims” Section 3.15(a) “Equity Commitment Letter” Section 4.9(b) “Equity Financing” Section 4.9(b) “Equity Investors” Section 4.9(b) “Equivalent Coverage” Section 5.9(c) “ERISA” Section 3.11(a) “ERISA Affiliate” Section 3.11(a) “Exchange Act” Section 1.1(a) “Expense Reimbursement Fee” Section 7.2(b)(v) “Expiration Date" ” Section 3.2(a1.1(d) "Company Common Stock" Recitals Term “Extended Outside Date” Section "Company Disclosure Letter" Article III "Company Equity Awards" 1.1(e) “Fairness Opinion” Section 2.4(e3.23 “FCPA” Section 3.8(d) "Company “Financing” Section 4.9(b) “Financing Alternative” Section 5.12(c) “Financing Commitments” Section 4.9(b) “Governmental Approval Condition” Annex I “Grant Date” 3.3 (b) “HSR Condition” Annex I “Inclusive Companies” Section 3.15(a) “Indemnification Agreements” Section 5.9(a) “Independent Director Approval” Section 1.8(d) “Independent Directors” Section 1.8(b) “Initial Expiration Date” Section 1.1(d) “Initial Outside Date” Section 1.1(e) “Lease Agreements” Section 3.13(a) “Leased Real Property" ” Section 3.17(b3.21(b) "Company Overlap Product" “Legal Proceeding” Section 6.2(c3.14 “Maximum Amount” Section 5.9(c) "Company Permits" “Merger” Recitals “Merger Consideration” Section 3.7(b2.1(a) "Company Preferred Stock" “Minimum Condition” Section 3.2(a1.1(a) "Company Remedial Action" “Multiemployer Plan” Section 6.2(c3.11(a) "Company Restricted Share Awards" “Nasdaq” Section 2.4(c1.1(e) "Company RSU Awards" “Notice Period” Section 2.4(b5.4(e)(1) "Company SEC “Offer” Recitals “Offer Documents" ” Section 3.4(a1.1(h) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" “Offer Price” Recitals

Terms Defined Elsewhere. Each of the following terms is defined has the meaning ascribed to such term in the Article or Section of this Agreement set forth opposite such term belowterm: Term Article/Section "Acceptable Confidentiality Agreement" Section 5.3(j)(iAcquired Company; Acquired Companies 3.3(b) "Agreement" Acquisition Proposal 6.6 Agreement Preamble "Amended and Restated Agreement" Allocation Statement 7.3(i) Applicable Limitation Date 7.1 Basket 7.2(c) Business Relation 7.7(b) Buyer Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Cap 7.2(c) Closing 2.3 Closing Date 2.3 Closing Estimate Statement 2.2 Closing Items 2.4(a) Closing Statement 2.4(a) Company Preamble "Bankruptcy and Equity Exception" Section 3.3(aCompany IP 3.11 Company Employee Benefit Plan 3.16(a) "BookDispute Notice 2.4(b) Effective Date Preamble Estimated Indebtedness 2.2 Estimated Foreign Withholding Amounts 2.2 Estimated Working Capital 2.2 Excess Amount 2.4(c) Financial Statements 3.4(a) Final Indebtedness 2.4(a) Final Foreign Withholding Amounts 2.4(a) Improvements 3.7 Indemnitee 7.2(g) Indemnitor 7.2(g) IRS 3.16(b) Xxxxx Preamble Latest Balance Sheet 3.4(a) Lease 3.7 Leased Real Property 3.7 Material Contract 3.10(b) Material Customers 3.21 Material Vendors 3.21 Monroe Preamble Outside Date 8.1(c) Parent Preamble Party Preamble Pre-Entry Shares" Section 2.2(aClosing Tax Period 7.3(a) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(aStraddle Period 7.3(c) "Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Purchased Units Recitals Term Article/Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(eRestricted Business 7.7(a) "Company Leased Real Property" Section 3.17(bRestricted Period 7.7(a) "Company Overlap Product" Section 6.2(cResolution Period 2.4(b) "Company Permits" Section 3.7(bSellers Preamble Seller Parties Preamble Subsidiaries 3.3(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section Shortfall Amount 2.4(c) "Company RSU Awards" Section 2.4(bTax Contest 7.3(d) "Company SEC Documents" Section 3.4(aTerminating Party 8.1(b) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Xxxx Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Units Recitals

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “2004 Incentive Plan” Section "Acceptable 6.10(f) “Affiliate Agreement” Recitals “Agreement” Preamble “Antitrust Filing” Section 6.5(b) “Balance Sheet” Section 3.10(c) “Benefits Date” Section 6.10(b) “Certificate” Section 2.1(a)(i) “Certificate of Merger” Section 1.2 “Change of Recommendation” Section 6.4(e) “Closing” Section 1.2 “Closing Date” Section 1.2 “Code” Recitals “Company” Preamble “Company Benefit Plan” Section 3.10 “Company Bylaws” Section 3.3 “Company Certificate” Section 3.3 “Company Common Stock” Section 2.1(a)(i) “Company Disclosure Letter” Article 3 “Company Financial Advisor” Section 3.23 “Company Form 10-K” Section 3.3 “Company Material Contract” Section 3.13 “Company Pension Plans” Section 3.10(a) “Company Permits” Section 3.7 “Company Preferred Stock” Section 3.4(a) “Company Recommendation” Section 6.1(c) “Company Rights Agreement” Section 2.1(c)(ii) “Company SEC Filings” Section 3.8(a) “Company Stockholder Approval” Section 3.24 “Company Stockholders’ Meeting” Section 6.2 “Company Subsidiaries” Section 3.1 “Company Welfare Plans” Section 3.10(a) “Confidentiality Agreement" ” Section 5.3(j)(i6.3(b) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" “Continuation Period” Section 6.10(b) “DGCL” Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Effective Time” Section 3.3(a1.2 “Employment Agreements” Recitals “ERISA Affiliate” Section 3.10(a) "Book-Entry Shares" “ESPP” Section 2.5 “Exchange Agent” Section 2.2(a) "Certificate of Merger" Section 1.3 "Certificates" “Exchange Fund” Section 2.2(a) "Change “FDA” Section 3.7 “FDCA” Section 3.7 “Former Superior Proposal” Section 6.4(d) “HMO” Section 3.10(i) Table of Recommendation" Contents “LLC Act” Recitals “Merger” Recitals “Merger Consideration” Section 5.3(d2.1(a)(i) "Closing" “Merger Sub” Preamble “Offering Memorandum” Section 1.2 "Closing 3.30 “Outside Date" ” Section 1.2 "Company" 8.1(b) “Owned Real Properties” Section 3.20(b) “Parent” Preamble "Company 401(k“Parent Bylaws” Section 4.2 “Parent Certificate” Section 4.2 “Parent Plans” Section 6.10(c) Plans" “Parent Rights Agreement” Section 6.7(c2.1(c)(i) "Company Acquisition “Parent SEC Filings” Section 4.6(a) “Parent Subsidiary” Section 4.9 “Proxy Statement” Section 6.1(a) “Registration Statement” Section 6.1(a) “Regulatory Conditions” Section 8.1(b) “Representatives” Section 6.3(a) “Xxxxxxxx-Xxxxx Act” Section 3.26 “Section 16” Section 6.19 “Stock Purchase Agreement" ” Section 5.3(d6.15 “Superior Proposal Notice” Section 6.4(c) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" “Surviving Entity” Section 1.1 "Dissenting Share" “Termination Fee” Section 2.3(a8.2(e)(i) "DOJ" “Transition Assistance Plans” Section 6.2(b2.4 “UK Stock Option Plans” Section 2.4 “VEBAs” Section 3.10(a) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" “Voting Agreements” Recitals

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “Affected Employees” Section "Acceptable Confidentiality 6.8(a) “Agreement" ” Preamble “Appraisal Rights” Section 5.3(j)(i2.3(a) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Base Premium” Section 3.3(a6.5(d) "“Book-Entry Shares" ” Section 2.2(b) “Certificate of Merger” Section 1.3 61 “Certificates” Section 2.2(b) “Change in Control Agreements” Section 6.8(d) “Change of Recommendation” Section 5.2(a) “Closing” Section 1.2 “Closing Date” Section 1.2 “Common Stock” Section 3.2(a) “Company” Preamble “Company Board of Directors” Recitals “Company Board Recommendation” Recitals “Company Disclosure Letter” Article III “Company Equity Awards” Section 2.4(c) “Company Equity Plan” Section 2.4(a) “Company Financial Advisor” Section 3.20 “Company Options” Section 2.4(a) “Company Permits” Section 3.18(b) “Company SEC Documents” Section 3.6 “Covered Persons” Section 6.5(b) “Debt Commitment Letter” Section 4.7 “DGCL” Recitals “Dissenting Shares” Section 2.3(a) “Effective Time” Section 1.3 “Equity Interests” Section 3.2(b) “Exchange Act” Section 1.6 “Exchange Fund” Section 2.2(a) "Certificate of Merger" “FCPA” Section 1.3 "Certificates" 3.25 “Financial Statements” Section 2.2(a3.6 “GAAP” Section 3.6 “Governmental Consents” Section 6.3(a) "Change of Recommendation" “Governmental Entity” Section 5.3(d3.5 “HSR Act” Section 3.5 “Indemnification Agreements” Section 6.5(a) "Closing" “Leases” Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k3.11(b) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company “Leased Real Property" ” Section 3.17(b3.11(b) "Company Overlap Product" “Legal Proceeding” Section 6.2(c3.13 “Match Period” Section 5.2(d) "Company Permits" “Merger” Recitals “Merger Consideration” Recitals “Notice of Superior Proposal or Intervening Event” Section 3.7(b5.2(d) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" “Offer” Recitals “Option Consideration” Section 2.4(a) "Competing Proposal" “Outside Date” Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals8.1(c)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “AFFILIATE” Section "Acceptable Confidentiality Agreement" 3.18 “AFFILIATE TRANSACTION” Section 5.3(j)(i3.18 “AGREEMENT” Preamble “ARTICLES OF MERGER” Section 1.3(a) "Agreement" “BREAK-UP FEE” Section 8.2(b) “CERCLA” Section 3.12 “CERTIFICATE” Section 2.2(b) “CLAIM” Section 6.5(b) “CLOSING” Section 1.4 “CLOSING DATE” Section 1.4 “COMPANY” Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" “COMPANY BOARD” Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “COMPANY BYLAWS” Section 3.3(a1.2(b) "Book-Entry Shares" “COMPANY COMMON SHARES” Recitals “COMPANY COMMON SHARE MERGER “CONSIDERATION” Section 2.2(a2.1(b) "Certificate of Merger" “COMPANY DECLARATION OF TRUST” Section 1.3 "Certificates" 1.2(a) “COMPANY DISCLOSURE SCHEDULE” Article III “COMPANY EMPLOYEES” Section 2.2(a6.8(a) "Change of Recommendation" 58 “COMPANY ENVIRONMENTAL PERMITS” Section 5.3(d3.12 “COMPANY FILED SEC REPORTS” Section 3.5 “COMPANY INTELLECTUAL PROPERTY RIGHTS” Section 3.20 “COMPANY LEASE” Section 3.9(h) "Closing" “COMPANY MATERIAL ADVERSE EFFECT” Section 1.2 "Closing Date" 3.1(a) “COMPANY PERMITS” Section 1.2 "Company" Preamble "Company 401(k3.25(a) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" “COMPANY PROPERTY” Section 3.9(a) "Company Board" “COMPANY RECOMMENDATION” Section 3.3(a6.1(c) "Company Board Recommendation" “COMPANY RESTRICTED SHARES” Section 3.3(a2.1(h) "Company Capitalization Date" “COMPANY RSEs” Section 3.2(a2.1(g) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company “COMPANY SEC Documents" REPORTS” Section 3.4(a) "Company Stock Option" “COMPANY SHARE OPTION” Section 2.4(a2.1(f) "Competing Proposal" “COMPANY SHARE BENEFIT PLANS” Section 5.3(j)(i2.1(f) "Continuing Employee" “COMPANY SHARE RIGHTS” Section 6.7(a3.2(c) "D&O Insurance Policy" “COMPANY SHAREHOLDER APPROVAL” Section 6.4 "DGCL" 3.3(b) “COMPANY SHAREHOLDERS MEETING” Section 1.1 "Dissenting Share" 6.1(c) “COMPANY SUBSIDIARY” Section 2.3(a3.1(b) "DOJ" “COMPANY TITLE INSURANCE POLICY” Section 6.2(b3.9(c) "Effective Time" “CONFIDENTIALITY AGREEMENT” Section 1.3 "Exchange Agent" 6.6(b) “CORPORATE BUDGET” Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals5.1

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(iAdjustment Excess Amount 2.4(d) "Agreement" Adjustment Shortfall Amount 2.4(d) Agreement Preamble "Amended Allocation Dispute 1.5(a) Allocation Dispute Notice 1.5(a) Allocation Resolution Period 1.5(a) Approval Motion 5.7(a) Approval Order 5.7(a)(i) Arbitrator 2.4(b) Assignment and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Assumption Agreement 1.3(b) Assumed Contracts 1.1(a)(vi) Assumed Liabilities 1.1(c) Assumed Real Property Leases 1.1(a)(x) Bankruptcy and Equity Exception" Exception 3.3 Bankruptcy Cases Recitals Bankruptcy Code Recitals Bankruptcy Court Recitals Bankruptcy Court Orders 5.7(a)(ii) Benefit Plan 3.11I Bidding Procedures 5.7(a)(ii) Bidding Procedures Order 5.7(a)(ii) Xxxx of Sale 2.2(a)(i) Books and Records 5.3(b)(i) Break-Up Fee 7.5(b)(ii) Business Recitals Closing 2.1 Closing Date 2.1 Code 1.5(a) Consent Asset 1.3(c) Conditional Approval Order 7.4(f) D&O Insurance 5.6(a) DinoKing Assumed Liabilities 1.1(c)(iv) DinoKing Insolvency Proceeding Cost 5.18(d) DinoKing Proceeding 5.18 Disclosure Letters Introduction to Article IV Dispute 1.5(b) Escrow Amount 2.3(b) Escrow Funds 2.3(b) Estimated Current Assets 2.3(b) Estimated Current Asset Statement 2.3(b) ERISA 3.11(c) Excluded Assets 1.1(b) Excluded Contracts Recitals Final Allocation Schedule 1.5(a) Final Current Assets 2.4(c) Financial Statements 3.5(a) Good Faith Deposit 1.4(a) Insurance Policies 5.1(b)(xi) Interim Period 5.1(a) Material Contract 3.10 Notice of Objection 2.4(a) Owned Real Property 3.12(a) Outside Date 7.4(j) PacBridge Parties Settlement 5.7(h) Permits 3.8(b) Proposed Allocation Schedule 1.5(a) Purchaser Preamble Purchaser Default Termination 1.4(b)(ii) Purchaser Disclosure Letter Introduction to Article IV Real Property 3.12(a) Real Property Lease Assignments 2.2(a)(iii) Real Property Leases 3.12(a) Registered Intellectual Property 3.14(a) Review Period 2.4(a) RMST Shares 3.2(b) RMST Securities 3.2(c) Section 3.3(a338(h)(10) "Book-Entry Shares" Section 2.2(aElection 5.10(d) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(a) "Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Seller Disclosure Letter" Letter Introduction to Article III "Company Equity Awards" Section 2.4(eSeller Employees 5.5(b) "Company Leased Real Property" Section 3.17(bSellers Preamble Service Provider 3.11(c) "Company Overlap Product" Section 6.2(cTitle Insurance Policy 5.16(a) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" RecitalsTransferred Employees 5.5(a)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(iAgent 3.2(a) "Agreement" Agent Agreement 3.2(a) Agreement Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 3.3(aAntitrust Laws 8.2(b) "Book-Entry Shares" Section 2.2(aAudited Driveline Financial Statements 8.12(a) "Base Premium 8.4(d) Certificate 3.2(b)(ii) Certificate of Merger" Merger 2.3 Closing 2.2 Closing Date 2.2 Covered Persons 8.4(a) Xxxx Preamble Xxxx Board Recitals Xxxx Board Recommendation Recitals Xxxx Common Stock 6.2(a) Xxxx Disclosure Letter VI Xxxx Equity Interests 6.2(a) Xxxx Financial Statements 6.7(b) Xxxx IP Agreements 6.16(b) Term Section 1.3 "Certificates" Section 2.2(aXxxx Material Contract 6.14(b) "Change of Recommendation" Section 5.3(dXxxx Permits 6.17(b) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(kXxxx Preferred Stock 6.2(a) Plans" Section 6.7(cXxxx SEC Documents 6.7(a) "Company Acquisition Agreement" Section 5.3(dXxxx Transaction Litigation 8.8 Debt Commitment Letter 6.24(a) "Company Benefit Plans" Section 3.9(aDivestiture Action 8.2(c) "Company Board" Section 3.3(aDriveline Agreements 5.9(a) "Company Board Recommendation" Section 3.3(aDriveline IP Agreements 5.11(b) "Company Capitalization Date" Section Driveline Material Contract 5.9(b) Driveline Permit 5.12(b) Effective Time 2.3 Enforceability Exceptions 4.2(a) Exchange Fund 3.2(a) "Company Excluded Information 8.10(c)(iv) Fee Letter 6.23(a) Financing 6.23(a) GKN Preamble GKN Board Recitals GKN Board Recommendation Recitals GKN Disclosure Letter IV GKN Transaction Litigation 8.8 Indemnification Agreements 8.4(a) Merger 2.1 Merger Consideration 3.1(a)(i) Merger Regulation 9.1(d)(i) Merger Sub Preamble Merger Sub Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(eStock 3.1(b) "Company Leased Real Property" Section 3.17(bNYSE 4.4 Required Amount 6.23 Xxxxxxxx-Xxxxx Act 6.7(a) "Company Overlap Product" Section 6.2(cSpinCo Preamble SpinCo Board 2.6(a)(i) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section SpinCo Options 3.4(a) "Company Stock Option" Section 2.4(aSpinCo PSUs 3.4(d) "Competing Proposal" Section 5.3(j)(iSpinCo RSUs 3.4(c) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section SpinCo SARs 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" RecitalsSurviving Corporation 2.1 Transaction Litigation 8.8 Unaudited Interim Driveline Financial Statements 8.12(b)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term Section "Acceptable 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Agreement Preamble Antitrust Approvals 4.3(b) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement" Section 5.3(j)(iAgreement 4.2 Contingent Payment 1.2(b) "Agreement" CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble "Amended and Restated Agreement" Party Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble "Bankruptcy and Equity Exception" Section 3.3(a) "Book-Entry Shares" Section 2.2(a) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(a) "Seller Board 2.3 Seller Change of Recommendation" Section 5.3(dRecommendation 4.7(a) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(kSeller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Plans" Section 6.7(cSeller FSA 9.3(a) "Company Acquisition Agreement" Section 5.3(dSeller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) "Company Benefit Plans" Section 3.9(aSeller SEC Documents Article II Seller Termination Fee 7.2(b)(i) "Company Board" Section 3.3(aSeller Trademarks 9.6 Shire Milestone Payment 9.4(a) "Company Board Recommendation" Section 3.3(aSpecified Milestone Payment 9.4(a) "Company Capitalization Date" Section 3.2(aStraddle Period 8.1(b)(i) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(eSublease 1.3(b)(xi) "Company Leased Real Property" Section 3.17(bSupply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) "Company Overlap Product" Section 6.2(cThird Party IP 2.9(b) "Company Permits" Section 3.7(bTrademark Assignment Agreement 1.3(b)(vii) "Company Preferred Stock" Section 3.2(aTransfer Taxes 8.1(a) "Company Remedial Action" Section 6.2(cTransferred Accounts Receivable 1.1(a)(xiv) "Company Restricted Share Awards" Section 2.4(cTransferred Inventory 1.1(a)(xi) "Company RSU Awards" Section 2.4(bTransferred IP 1.1(a)(iv) "Company SEC Documents" Section 3.4(aTransferred IP Agreements 2.9(b) "Company Stock Option" Section 2.4(aTransferred IP Documentation 1.1(a)(vi) "Competing Proposal" Section 5.3(j)(iTransferred Permits 1.1(a)(iv) "Continuing Employee" Section 6.7(aTransition Services Agreement 1.3(b)(x) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(aUpfront Payment 1.2(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" RecitalsUpward Adjustment Amount 1.4(c)(ii)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Defined Term Section "Acceptable Confidentiality “Agreement" ” Preamble “Alternative Acquisition Agreement” Section 5.3(j)(i5.5(d) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "“Bankruptcy and Equity Exception" Equitable Exceptions” Section 3.3(a) "Book-Entry Shares" Section 2.2(a) "“Certificate of Merger" ” Section 1.3 "“Certificates" ” Section 2.2(a2.2(b) "“Change of Board Recommendation" ” Section 5.3(d5.5(d) "“Claim” Section 5.10(a) “Closing" ” Section 1.2 "“Closing Date" ” Section 1.2 "“Common Shares” Section 2.1(a) “Common Share Merger Consideration” Section 2.1(a) “Company" ” Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "“Company Benefit Plans" Plan” Section 3.9(a3.12(a) "Defined Term Section “Company Board" ” Section 3.3(a3.3(b) "“Company Board Recommendation" ” Section 3.3(a5.2(c) "“Company Capitalization Date" Bylaws” Section 3.2(a3.1(b) "“Company Common Stock" Recitals Term Certificate” Section "3.1(b) “Company Disclosure Letter" Schedule” Article III "3 “Company Equity Awards" Financial Advisor” Section 2.4(e3.22 “Company Financial Statements” Section 3.8(c) "“Company Leased Real Intellectual Property" ” Section 3.17(b) "“Company Overlap Product" Material Contract” Section 6.2(c3.14(a) "“Company Options” Section 2.3 “Company Permits" ” Section 3.7(b3.7(a) "“Company Preferred Stock" Representatives” Section 3.2(a5.4(a) "“Company Remedial Action" Rights Agreement” Section 6.2(c3.3(b) "“Company Restricted Share Awards" Rights Agreement Amendment” Section 2.4(c3.3(b) "Company RSU Awards" Section 2.4(b) "“Company SEC Documents" ” Section 3.4(a3.8(a) "“Company Stock Option" Option Plans” Section 2.4(a2.3 “Company Stockholder Approval” Section 3.4 “Confidentiality Agreement” Section 5.4(b) "Competing Proposal" “Continuing Employees” Section 5.3(j)(i5.9(a) "Continuing Employee" “D&O Insurance” Section 6.7(a5.10(b) "D&O Insurance Policy" Section 6.4 "“DGCL" ” Section 1.1 "“Dissenting Share" Shares” Section 2.3(a2.1(f)(i) "DOJ" Section 6.2(b) "“Effective Time" ” Section 1.3 "Exchange Agent" “ERISA” Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals3.12(a)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “Adjustment” Section "Acceptable Confidentiality 2.1(f) “Agreement" ” Preamble “Alternative Acquisition Agreement” Section 5.3(j)(i5.4(d) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Alternative Financing” Section 3.3(a5.13(c) "“Articles of Merger” Section 1.2 “Benefit Protection Period” Section 5.9(a) “Book-Entry Shares" ” Section 2.2(a2.2(b) "Certificate of Merger" “Cash Consideration” Section 1.3 "Certificates" 2.1(a) “Certificate” Section 2.2(a2.1(b) "“Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" ” Section 3.3(a5.4(a) "“Change of Parent Board Recommendation” Section 5.2(e) “Closing” Section 1.2 “Closing Date” Section 1.2 “Commitment Letter” Section 4.18(b) “Company” Preamble “Company Capitalization Date" Benefit Plan” Section 3.12(a) “Company Board” Recitals “Company Board Recommendation” Section 5.2(d) “Company Bylaws” Section 3.1(b) “Company Charter” Section 3.1(b) “Company Common Stock” Section 3.2(a) "“Company Common Stock" Recitals Term Designee” Section "5.20 “Company Disclosure Letter" ” Article III "3 “Company Employees” Section 5.9(a) “Company Equity Awards" Plans” Section 2.4(e2.4(a) "“Company Financial Statements” Section 3.7(b) “Company Insurance Policies” Section 3.22 “Company Leased Real Property" ” Section 3.17(b3.16(b) "“Company Overlap Product" Options” Section 6.2(c2.4(a) "“Company Owned Real Property” Section 3.16(a) “Company Permits" ” Section 3.7(b3.6(a) "“Company Preference Stock” Section 3.2(a) “Company Preferred Stock" ” Section 3.2(a) "“Company Remedial Action" Real Property” Section 6.2(c3.16(c) "“Company Restricted Share Awards" Real Property Lease” Section 2.4(c3.16(b) "“Company RSU Awards" Real Property Rights” Section 2.4(b3.16(c) "“Company Representatives” Section 5.3(a) “Company Required Governmental Approvals” Section 3.5 “Company Scheduled Contract” Section 3.14(b) “Company SEC Documents" ” Section 3.4(a3.7(a) "“Company Stock Option" Shareholder Approval” Section 2.4(a3.3(c) "Competing Proposal" “Company Subsidiary” Section 5.3(j)(i3.1(c) "Continuing Employee" “Company Tax Certificates” Section 6.7(a5.18(d) "“Company Termination Fee” Section 7.2(b)(i) “Company Trading Guidelines” Section 3.24 “Confidentiality Agreements” Section 5.3(c) “CPUC” Section 3.5(c) “D&O Insurance Policy" Insurance” Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals5.11(b)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Defined Term Section "Acceptable Confidentiality “1933 Act” 8.3 “Affiliate” 8.3 “Affiliate Letters” 5.19 “Agreement" Section 5.3(j)(i) "” Preamble “Ancillary Documents” 8.3 “Approval” 8.3 “Bxxxxxxxx Employment Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 3.3(a) "Book-Entry Shares" Section 2.2(a) "” 5.16.2 “Certificate of Merger" Section 1.3 "Certificates" Section 2.2(a) "Change of Recommendation" Section 5.3(d) "” 1.2 “Closing" Section ” 1.2 "“Closing Date" ” 1.2 Defined Term Section “Code” Recitals “Dissenting Shares” 2.4 “Dissenting Shareholders” 2.4 “D&O Insurance Policy” 5.13.2 “Effective Time” 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company “Employee Benefit Plans" ” 3.21.1 “Environmental Claim” 8.3 “Environmental Laws” 8.3 “ERISA” 3.21.1 “ERISA Affiliate” 3.21.1 “Exchange Act” 8.3 “Exchange Agent” 8.3 “Exchange Fund” 2.2.1 “Exchange List” 2.1.2 “Existing Parent Indebtedness” 8.3 “Expenses” 8.3 “GAAP” 8.3 “Governmental Authority” 8.3 “Hazardous Materials” 8.3 “Hxxxxx Employment Agreement” 5.16.3 “Hydrocarbons” 8.3 “Interim Period” 5.1 “Knowledge” 8.3 “Lands” 8.3 “Laws” 8.3 “Leases” 8.3 “Liability” 8.3 “Lien” 8.3 “Litigation” 8.3 “Merger” Recitals “Merger Consideration” 2.1.1 “Merger Sub” Preamble “Monthly Unaudited Financial Information” 5.15 “NASD” 8.3 “Net Revenue Interest” 8.3 “NRS” Recitals “Oil & Gas Interests” 8.3 “OTC Bulletin Board” 8.3 “Other Filings” 8.3 “Parent” Preamble “Parent Acquisition Proposal” 8.3 “Parent Assets” 4.17(c) “Parent Board” Recitals “Parent Capital Securities” 8.3 80 Defined Term Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company “Parent Common Stock" Recitals Term Section "Company Disclosure ” 8.3 “Parent Diligence Letter" ” Preamble to Article III "Company Equity Awards" Section 2.4(e) "Company IV “Parent Document(s)” 4.3.1 “Parent Financial Statements” 5.15 “Parent Governing Documents” 4.2 “Parent Leased Real Property" Section 3.17(b” 4.16(b) "Company Overlap Product" Section 6.2(c) "Company “Parent Material Adverse Effect” 8.3 “Parent Options” 4.4.1 “Parent Permits" Section 3.7(b) "Company ” 4.12 “Parent Preferred Stock" ” 8.3 “Parent Real Property Leases” 4.16(b) “Parent Representatives” 5.6.1 “Parent Scheduled Contracts” 4.18.1(a) “Parent SEC Filings” 4.8.1 “Parent Shareholder” 8.3 “Parent Shareholder Approval” 4.3.3 “Parent Shareholder Voting Agreement” 6.3.14 “Parent Shareholders’ Meeting” 5.5.1 “Parent Stock Option Plans” 4.4.3 “Parent Superior Proposal” 8.3 “Permitted Liens” 8.3 “Permit” 8.3 “Person” 8.3 “Proxy Statement” 5.4.1(a) “Quarterly Unaudited Financial Information” 5.15 “Related Parties” 3.25(a) “Release” 8.3 “Registration Statement” 5.4.1(b) “Reserve Report” 8.3 “SEC” 8.3 “Subsidiary” 8.3 “Surviving Corporation” 1.1 “Target” Preamble “Target Acquisition Proposal” 8.3 “Target Assets” 3.15(c) “Target Board” Recitals “Target Certificate(s)” 2.2.2 “Target Common Stock” 8.3 “Target Diligence Letter” Preamble to Article III “Target Document(s)” 3.3.1 “Target Employees” 5.12 “Target Filings” 3.8.1(a) “Target Financial Statements” 3.8.2(a) “Target Governing Documents” 3.2 81 Defined Term Section 3.2(a“Target Leased Real Property” 3.14(b) "Company Remedial Action" Section 6.2(c“Target Material Adverse Effect” 8.3 “Target Permits” 3.12 “Target Real Property Leases” 3.14(b) "Company Restricted Share Awards" Section 2.4(c“Target Representatives” 5.6.1 “Target Scheduled Contracts” 3.16.1(a) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing “Target Shareholder” 8.3 “Target Shareholder Approval” 3.3.3 “Target Shareholders’ Meeting” 5.5.2 “Target Shareholder Voting Agreement” 6.2.14 “Target Superior Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" ” 8.3 “Tax(es)” 8.3 “Tax Law” 8.3 “Tax Period” 8.3 “Tax Return” 8.3 “TBCA” Recitals

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “Affected Employees” Section "Acceptable Confidentiality 6.8(a) “Agreement" ” Preamble “Appraisal Rights” Section 5.3(j)(i2.3(a) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Base Premium” Section 3.3(a6.5(d) "“Book-Entry Shares" ” Section 2.2(b) “Certificate of Merger” Section 1.3 “Certificates” Section 2.2(b) “Change in Control Agreements” Section 6.8(d) “Change of Recommendation” Section 5.2(a) “Closing” Section 1.2 “Closing Date” Section 1.2 “Common Stock” Section 3.2(a) “Company” Preamble “Company Board of Directors” Recitals “Company Board Recommendation” Recitals “Company Disclosure Letter” Article III “Company Equity Awards” Section 2.4(c) “Company Equity Plan” Section 2.4(a) “Company Financial Advisor” Section 3.20 “Company Options” Section 2.4(a) “Company Permits” Section 3.18(b) “Company SEC Documents” Section 3.6 “Covered Persons” Section 6.5(b) “Debt Commitment Letter” Section 4.7 “DGCL” Recitals “Dissenting Shares” Section 2.3(a) “Effective Time” Section 1.3 “Equity Interests” Section 3.2(b) “Exchange Act” Section 1.6 “Exchange Fund” Section 2.2(a) "Certificate “FCPA” Section 3.25 “Financial Statements” Section 3.6 “GAAP” Section 3.6 “Governmental Consents” Section 6.3(a) “Governmental Entity” Section 3.5 “HSR Act” Section 3.5 “Indemnification Agreements” Section 6.5(a) “Leases” Section 3.11(b) “Leased Real Property” Section 3.11(b) “Legal Proceeding” Section 3.13 “Match Period” Section 5.2(d) “Merger” Recitals “Merger Consideration” Recitals “Notice of Merger" Superior Proposal or Intervening Event” Section 1.3 "Certificates" 5.2(d) “Offer” Recitals “Option Consideration” Section 2.4(a) “Outside Date” Section 8.1(c) “Owned Intellectual Property” Section 3.12(a) “Owned Real Property” Section 3.11(a) “Parent” Preamble “Parent Disclosure Letter” Article IV “Paying Agent” Section 2.2(a) "Change of Recommendation" “Permitted Liens” Section 5.3(d3.11(a) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" “Preferred Stock” Section 3.2(a) "Company “Proxy Statement” Section 1.6(a) “Purchaser” Preamble “Purchaser Common Stock" Recitals Term ” Section "Company Disclosure Letter" Article III "Company Equity Awards" 2.1 62 “Regulatory Law” Section 2.4(e6.3(e) "Company Leased Real Property" “Regulatory Material Adverse Effect” Section 3.17(b6.3(c) "Company Overlap Product" “Requisite Stockholder Approval” Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company 3.21 “Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Share” Section 2.4(b) "Company SEC Documents" “Reverse Termination Fee” Section 3.4(a8.2(c) "Company Stock Option" “Xxxxxxxx-Xxxxx Act” Section 2.4(a3.6 “SEC” Section 1.6 “Securities Act” Section 3.6 “Settlement Action” Section 6.3(c) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" “Shares” Recitals

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term Section "Acceptable Confidentiality Acquisition Agreement" Section 5.3(j)(i6.3(d) "Additional Shortfall" Section 3.2(b)(iii) "Adverse Recommendation Change" Section 6.3(d) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity ExceptionAlternate Financing" Section 3.3(a7.10(c) "Articles of Merger" Section 2.3 "Book-Entry Share" Section 3.1(b) "Cash Consideration" Section 3.1(a)(ii)(A) "Cash Election" Section 3.1(a)(ii)(A) "Cash Election Number" Section 3.2(b)(ii) "Cash Election Shares" Section 2.2(a3.1(a)(ii)(A) "Certificate of MergerCertificate" Section 1.3 "Certificates" Section 2.2(a) "Change of Recommendation" Section 5.3(d3.1(b) "Closing" Section 1.2 2.2 "Closing Date" Section 1.2 2.2 "Commitment Letter" Section 5.28(a) "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Advisor Related Agreement" Section 5.3(d) 4.23 "Company Benefit PlansAgreements" Section 3.9(a) "Company Board" Section 3.3(a4.13(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III IV "Company Equity AwardsFinancial Advisor" Section 2.4(e4.20 "Company Financial Statements" Section 4.6 "Company Leases" Section 4.18(e) "Company Leased Real PropertyMaterial Contract" Section 3.17(b4.13(b) "Company Overlap ProductPending Acquisitions" Section 6.2(c6.1(a)(vi) "Company Permits" Section 3.7(b4.17(b) "Company Permitted Liens" Section 4.18(b) "Company Preferred Stock" Section 3.2(a4.2(a) "Company Remedial ActionProperty(ies)" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b4.18(a) "Company SEC Documents" Section 3.4(a4.6 "Company Subsidiary Partnership" Section 4.12(g) "Company Stock OptionTax Protection Agreements" Section 2.4(a4.12(g) "Company Tax Representation Letter" Section 6.1(b) "Company Third Party" Section 4.18(h) "Company Title Insurance Policy(ies)" Section 4.18(j) "Company Voting Debt" Section 4.2(a) "Competing Proposal" Section 5.3(j)(i6.3(g) "Continuing EmployeeCovered Persons" Section 6.7(a7.5(a) "D&O Insurance PolicyInsurance" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b7.5(d) "Effective Time" Section 1.3 2.3 "Election" Section 3.3(a) "Election Deadline" Section 3.3(d) "Exchange Agent" Section 2.2(a3.3(d) "Exchange Agent Agreement" Section 3.3(d) "Exchange Fund" Section 2.2(a3.4 "Financing" Section 5.28(a) "Execution Form of Election" Section 3.3(b) "Holder" Section 3.3 "Indemnification Agreements" Section 7.5(a) "Interim Period" Section 6.1(a) "Legal Proceeding" Section 4.10 "Mailing Date" Preamble Section 3.3(c) "FDA LawsMaster Leases" Section 3.13(a4.18(e) "Federal Health Care ProgramsMaximum Cash Conversion Number" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a3.2(a)(i) "Merger" RecitalsRecitals "Merger Consideration" Section 3.1(a)(ii) "Merger Sub" Preamble "MGCL" Recitals "Minimum Cash Conversion Number" Section 3.2(a)(ii) "Minimum Cash Conversion Number Shortfall" Section 3.2(b)(iii)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “2004 Incentive Plan” Section "Acceptable 6.10(f) “Affiliate Agreement” Recitals “Agreement” Preamble “Antitrust Filing” Section 6.5(b) “Balance Sheet” Section 3.10(c) “Benefits Date” Section 6.10(b) “Certificate” Section 2.1(a)(i) “Certificate of Merger” Section 1.2 “Change of Recommendation” Section 6.4(e) “Closing” Section 1.2 “Closing Date” Section 1.2 “Code” Recitals “Company” Preamble “Company Benefit Plan” Section 3.10 “Company Bylaws” Section 3.3 “Company Certificate” Section 3.3 “Company Common Stock” Section 2.1(a)(i) “Company Disclosure Letter” Article 3 “Company Financial Advisor” Section 3.23 “Company Form 10-K” Section 3.3 “Company Material Contract” Section 3.13 “Company Pension Plans” Section 3.10(a) “Company Permits” Section 3.7 “Company Preferred Stock” Section 3.4(a) “Company Recommendation” Section 6.1(c) “Company Rights Agreement” Section 2.1(c)(ii) “Company SEC Filings” Section 3.8(a) “Company Stockholder Approval” Section 3.24 “Company Stockholders’ Meeting” Section 6.2 “Company Subsidiaries” Section 3.1 “Company Welfare Plans” Section 3.10(a) “Confidentiality Agreement" ” Section 5.3(j)(i6.3(b) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" “Continuation Period” Section 6.10(b) “DGCL” Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" “Effective Time” Section 3.3(a1.2 “Employment Agreements” Recitals “ERISA Affiliate” Section 3.10(a) "Book-Entry Shares" “ESPP” Section 2.5 “Exchange Agent” Section 2.2(a) "Certificate of Merger" Section 1.3 "Certificates" “Exchange Fund” Section 2.2(a) "Change of Recommendation" “FDA” Section 5.3(d3.7 “FDCA” Section 3.7 “Former Superior Proposal” Section 6.4(d) "Closing" “HMO” Section 1.2 "Closing 3.10(i) 74 “LLC Act” Recitals “Merger” Recitals “Merger Consideration” Section 2.1(a)(i) “Merger Sub” Preamble “Offering Memorandum” Section 3.30 “Outside Date" ” Section 1.2 "Company" 8.1(b) “Owned Real Properties” Section 3.20(b) “Parent” Preamble "Company 401(k“Parent Bylaws” Section 4.2 “Parent Certificate” Section 4.2 “Parent Plans” Section 6.10(c) Plans" “Parent Rights Agreement” Section 6.7(c2.1(c)(i) "Company Acquisition “Parent SEC Filings” Section 4.6(a) “Parent Subsidiary” Section 4.9 “Proxy Statement” Section 6.1(a) “Registration Statement” Section 6.1(a) “Regulatory Conditions” Section 8.1(b) “Representatives” Section 6.3(a) “Xxxxxxxx-Xxxxx Act” Section 3.26 “Section 16” Section 6.19 “Stock Purchase Agreement" ” Section 5.3(d6.15 “Superior Proposal Notice” Section 6.4(c) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(e) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" “Surviving Entity” Section 1.1 "Dissenting Share" “Termination Fee” Section 2.3(a8.2(e)(i) "DOJ" “Transition Assistance Plans” Section 6.2(b2.4 “UK Stock Option Plans” Section 2.4 “VEBAs” Section 3.10(a) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" “Voting Agreements” Recitals

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term “401(k) Plan” Section "Acceptable Confidentiality 6.12 “After Consultation” Section 5.2(b) “Agreement" ” Introduction “Appointment Date” Section 5.3(j)(i5.1 “Appointment Time” Section 1.3 “Appraisal Rights” Section 2.3(a) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "“Assignee” Section 9.13 “Balance Sheet Date” Section 3.8(a) “Bankruptcy and Equity Exception" Claims/Interest Section 3.3(a3.25(b) "Book-Entry Shares" “Bankruptcy Confirmation Order” Section 2.2(a3.25 “Base Premium” Section 6.6(d) "“Benefit Plans” Section 3.11(a) “Certificate of Merger" ” Section 1.3 "1.5 “Certificates" ” Section 2.2(a2.2(b) "Change of Recommendation" “Closing” Section 5.3(d) "Closing" Section 1.2 "1.6 “Closing Date" ” Section 1.2 "Company" Preamble "Company 401(k1.6 “Code” Section 2.2(e) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" “Common Stock” Section 3.2(a) "“Company” Introduction “Company Common Stock" Agreements” Section 3.5(a) “Company Board of Directors” Recitals Term “Company Bylaws” Section "1.3(b) “Company Certificate” Section 1.3(b) “Company Change in Recommendation” Section 5.3(b) “Company Collective Bargaining Agreement” Section 3.16(a) “Company Disclosure Letter" Schedule” Article III "“Company Equity Awards" Financial Advisor” Section 2.4(e3.20 “Company Governing Documents” Section 1.3(b) "“Company Leased Real Property" IP Agreements” Section 3.15(d) “Company Material Contract” Section 3.13 “Company Options” Section 2.5(a) “Company Permits” Section 3.17(b) "“Company Overlap Product" Recommendation” Section 6.2(c5.3(a) "“Company Permits" Section 3.7(b) "Company Preferred Stock" Rights” Section 3.2(a) "“Company Remedial Action" Rights Agreement” Section 6.2(c3.2(a) "“Company Restricted Share Awards" Scheduled Agreements” Section 2.4(c3.5(a) "Company RSU Awards" Section 2.4(b) "“Company SEC Documents" ” Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(a) "Merger" Recitals3.6(a)

Terms Defined Elsewhere. Each of the The following terms is are defined elsewhere in the Section of this Agreement set forth opposite such term Agreement, as indicated below: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(i) "Agreement" Preamble "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 3.3(a) "Book-Entry Shares" Section 2.2(a) "Certificate of Merger" Section 1.3 1.2 "Certificates" Section 2.2(a) "Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 2.2.2 "Company" Preamble "Company 401(k) PlansBenefit Plan" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) 3.12.1 "Company Board" Section 3.3(a) Recitals "Company Board RecommendationBy-laws" Section 3.3(a) 3.2 "Company Capitalization DateCertificate" Section 3.2(a) 3.2 "Company Common Stock" Recitals Term Section 2.1.1 "Company Disclosure LetterSchedule" Article III 3 "Company Equity AwardsEmployees" Section 2.4(e) 5.10 "Company Financial Advisor" Section 3.17 "Company Leased Real Property" Section 3.17(b) 3.8.1 "Company Overlap ProductMaterial Contract" Section 6.2(c) 3.11 "Company Options" Section 2.5 "Company Owned Property" Section 3.8.1 "Company Permits" Section 3.7(b) 3.19.1 "Company Preferred StockReal Property" Section 3.2(a) 3.8.1 "Company Remedial ActionRepresentatives" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) 5.5 "Company SEC DocumentsFilings" Section 3.4(a) 3.5.1 "Company Stock OptionStockholders' Meeting" Section 2.4(a) 5.4 "Competing ProposalCompany Subsidiaries" Section 5.3(j)(i) 3.1 "Continuing EmployeeD&O Insurance" Section 6.7(a) 5.11.2 "D&O Insurance PolicyDissenting Stockholders" Section 6.4 2.1.1 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) Recitals 38 "Effective Time" Section 1.3 1.2 "Exchange ERISA" Section 3.12.1 "ERISA Affiliate" Section 3.12.1 "Xxxxxx Street Agreement" Section 3.8.11 "IRS" Section 3.7.5 "Lease Documents" Section 3.8.3 "Material Intellectual Property" Section 3.10 "Merger" Recitals "Merger Consideration" Section 2.1.1 "Merger Sub" Preamble "Multiemployer Plan" Section 3.12.3 "Option Payment" Section 2.5 "Outside Date" Section 7.1.2 "Parent" Preamble "Parent Benefit Plan" Section 5.10 "Parent Disclosure Schedule" Article 4 "Parent Representatives Section 5.5 "Parent Subsidiaries" Recitals "Paying Agent" Section 2.2(a) 2.2.1 "Exchange Payment Fund" Section 2.2(a) 2.2.1 "Execution Date" Preamble "FDA LawsPBGC" Section 3.13(a) 3.12.4 "Federal Health Care ProgramsPermitted Exceptions" Section 3.13(j) 3.8.2 "FTCProxy Statement" Section 6.2(b) 5.3.1 "GAAPQualifying Acquisition Proposal" Section 3.4(b) 5.6.1 "GLPRegulatory Conditions" Section 3.13(c) 7.1.2 "HIPAARequisite Stockholder Approval" Section 3.13(i) 3.18 "INDSchedule 13E-3" Section 3.13(d) 5.3.1 "Indemnified PartiesSeparation Agreements" Recitals "Special Committee" Recitals "Surviving Corporation" Section 6.4 1.1 "Material ContractsSurveys" Section 3.20(a) 3.8.2 "MergerTaxes" Section 3.7.13 "Tax Return" Section 3.7.13 "Terminating Company Breach" Section 7.1.5 39 "Terminating Parent Breach" Section 7.1.6 "Title Policies" Section 3.8.2 "Voting Agreements" Recitals

Terms Defined Elsewhere. Each The following is a list of the following additional terms is defined used in this Agreement and a reference to the Section of this Agreement set forth opposite hereof in which such term belowis defined: Term Section "Acceptable Confidentiality Agreement" Section 5.3(j)(i2004 and 2005 Statement of Net Sales 3.13(a) "Agreement" 2004 and 2005 S-X Business Financials 3.13(b) Accounting Practices 2.6(b) Acquired Assets 2.2 Action 3.7 Agreement Preamble "Amended Assumed Contracts 2.2(a)(iii) Assumed Liabilities 2.4(a) Assumed Union Contract 5.18(a) BAS 3.12 Buncher 5.9 Buncher Parking Lease 5.9 Business Recitals Business Employees 5.18(a) Buyer Preamble Buyer Certificate 6.2(d) Buyer Disclosure Letter Article IV (Intro) Buyer Indemnified Parties 8.2(a) Buyer’s Health and Restated Agreement" Welfare Plans 5.18(f)(i) Buyer’s Pension Plans 5.18(g) Buyer Retiree Health Plan 5.18(c)(ii) Buyer’s Savings Plans 5.18(h)(i) Buyer Third Party Consents 5.15(b) Calculation Notice 2.6(e) Closing 7.1 Closing Date 7.1 Closing Date Interest Rate 2.6(h) Closing Working Capital 2.6(a) Collateral Source 8.3(c) College Inn Co-Pack Agreement 5.6 Company Preamble "Amended Company Certificate 6.1(d) Company Contracts 2.2(a)(iii) Company Disclosure Letter Article III (Intro) Company Health and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 3.3(aWelfare Plans 5.18(f)(i) "Book-Entry Shares" Section 2.2(aCompany Indemnified Parties 8.2(b) "Certificate of Merger" Section 1.3 "Certificates" Section 2.2(aCompany Pension Plans 5.18(g) "Change of Recommendation" Section 5.3(d) "Closing" Section 1.2 "Closing Date" Section 1.2 "Company" Preamble "Company 401(k) Plans" Section 6.7(c) "Company Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock" Recitals -7- Term Section "Company Disclosure Letter" Article III "Company Equity Awards" Section 2.4(eThird Party Consents 5.15(a) "Company Confidentiality Agreement 5.26 Contracts 2.2(a)(iii) Co-Pack Agreements 5.6 Cost Neutral Basis 2.8(a) Credit Agreement 4.3 Critical Dividable Contracts 2.8(a) DCB Recital Deed 6.1(h)(iii) Easement Agreement 5.17(b) Employee Retention Agreements 3.8 Employee Services Agreement 5.13 Energy Supply Agreement 5.12 Environmental Investigation 5.4 Equipment 2.2(a)(i) Estimated Working Capital 2.6(c) Excluded Assets 2.3 Excluded Liabilities 2.4(b) Facilities License 5.10 Financial Statements 3.13(a) First Option to Purchase 3.4(a) Form Working Capital Statement 2.6(a) FSS Recitals Heinz IP Consent 5.15(d) Indemnified Party 8.2(c) Indemnifying Party 8.2(c) Initial Calculation 2.6(d) Intellectual Property 2.2(a)(ii) Interim S-X Business Financials 5.32(a) Inventory 2.2(a)(vii) Leased Real Property" Section 3.17(bProperty 2.2(a)(v) "Company Overlap Product" Section 6.2(cLiens 3.3 Losses 8.2(a) "Company Permits" Section 3.7(bLosses Threshold 8.3(a) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section Material Contracts 3.8 May 1, 2005 Statement of Net Assets 3.13(a) "Federal Health Care Programs" Mendota Co-Occupancy Agreement 5.7 Mendota Lease Agreement 5.7 Mendota Sublease Agreement 5.7 Multiemployer Plan 3.15(a) Names 5.21 Nature’s Goodness Recitals Other Dividable Contracts 2.8(c) Owned Real Property 2.2(a)(iv) Parking Sublease 5.9 PBGC 5.18(g)(ii)(B) Term Section 3.13(jPost Closing Dividable Contracts 2.8(c) "FTC" Section 6.2(bPT 5.29 Purchase Price 2.5 Real Estate Leases 3.5 Rebate Contracts 5.24 Rebate Statement 5.24 Regulation S-X 3.13(b) "GAAP" Section 3.4(bRetained Pittsburgh Real Property 2.3(f) "GLP" Section 3.13(cR&D Equipment Room Lease 5.11 R&D Lease & Facility Sharing Agreement 5.11 SEC 3.13(b) "HIPAA" Section 3.13(iSettlement Accountants 2.6(f) "IND" Section 3.13(dSeverance Plans 5.18(f)(v) "Indemnified Parties" Section 6.4 "Material Contracts" Section 3.20(aShared Del Monte IP Agreement 5.8 Shared IP Agreements 5.8 Shared TreeHouse IP Agreement 5.8 Statement of Net Assets 3.13(a) "Merger" RecitalsStatement of Net Sales 3.13(a) Survival Date 8.1 Surveys 6.1(h)(ii) S-X Business Financials 5.32(a) Terminal Island Co-Pack Agreement 5.6 TIF Agreement 2.4(a)(xiv) Title Commitments 6.1(h)(i) Trademark License Agreement 5.8 Transferred Employees 5.18(a) Transferred Union Employee 5.18(a) Transferred Mendota Union Employees 5.18(c)(i) Transition Services Agreement 5.5 Union Pension Fund 5.18(g)(ii) WARN 5.18(b) WARN Act Laws 5.18(b) Working Capital 2.6(a) Working Capital Adjustment Amount 2.6(g) Working Capital Target 2.6(a)